Octreotide
Also referenced as: Sandostatin
A somatostatin analogue used to control specific excess-hormone and secretory symptoms.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved formulations cover specified acromegaly and carcinoid or VIPoma symptom indications. One formulation’s indication does not apply automatically to all products.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A somatostatin analogue used to control specific excess-hormone and secretory symptoms.
FDA-approved formulations cover specified acromegaly and carcinoid or VIPoma symptom indications. One formulation’s indication does not apply automatically to all products.
Immediate-release, depot and other formulations have different labels; symptom control is not proof of tumor cure.
Why It's Being Studied
- Acromegaly
- Carcinoid symptoms
- VIPoma symptoms
Mechanism of Action
Somatostatin-receptor activation inhibits growth hormone and several gastrointestinal hormones.
Somatostatin-receptor activation inhibits growth hormone and several gastrointestinal hormones. Immediate-release, depot and other formulations have different labels; symptom control is not proof of tumor cure.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Acromegaly
- Carcinoid symptoms
- VIPoma symptoms
- Injectable approved formulations
- Product-specific oral formulation
Evidence Summary
Human studies demonstrate biochemical and secretory-symptom control in the approved disease settings.
Higher tiers carry more weight. Filled tiers have evidence for Octreotide; tap to read it.
- Human studies demonstrate biochemical and secretory-symptom control in the approved disease settings.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Human studies demonstrate biochemical and secretory-symptom control in the approved disease settings.
Reported Adverse Events in Research
- Gallstones, glucose changes, bradycardia and fat malabsorption are important adverse effects.
Limitations of Current Evidence
- Immediate-release, depot and other formulations have different labels; symptom control is not proof of tumor cure.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Octreotide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Injectable approved formulations, Product-specific oral formulation | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Octreotide — prescribing label